| Bioactivity | Pparδ agonist 5, an orally active PPARδ-selective agonist (EC50=0.335 μM), is much greater than that of the prototypical standard GW0742. Pparδ agonist 5 promotes improvements in bone density and microarchitecture in vivo[1]. |
| In Vivo | Pparδ agonist 5 (compound 31a) shows an even greater improvement in the trabecular structure, comparable to or slightly better than GW0742[1]. Animal Model: |
| Name | Pparδ agonist 5 |
| Formula | C23H21F3N2O2S |
| Molar Mass | 446.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kress BJ, et al. Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis. J Med Chem. 2021;64(10):6996-7032. |